Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(5-6):888–894. doi: 10.1038/sj.bjc.6690142

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer

J A Foekens 1, E P Diamandis 1, H Yu 3, M P Look 3, M E Meijer-van Gelder 3, J G M Klijn 1
PMCID: PMC2362687  PMID: 10070886

Abstract

Prostate-specific antigen (PSA) is a serine protease which may play a role in a variety of cancer types, including breast cancer. In the present study, we evaluated whether the level of PSA in breast tumour cytosol could be associated with prognosis in primary breast cancer, or with response to tamoxifen therapy in recurrent disease. PSA levels were determined by enzyme-linked immunosorbent assay (ELISA) in breast tumour cytosols, and were correlated with prognosis in 1516 patients with primary breast cancer and with response to first-line tamoxifen therapy in 434 patients with recurrent disease. Relating the levels of PSA with classical prognostic factors, low levels were more often found in larger tumours, tumours of older and post-menopausal patients, and in steroid hormone receptor-negative tumours. There was no significant association between the levels of PSA with grade of differentiation or the number of involved lymph nodes. In patients with primary breast cancer, PSA was not significantly related to the rate of relapse, and a positive association of PSA with an improved survival could be attributed to its relationship to age. In patients with recurrent breast cancer, a high level of PSA was significantly related to a poor response to tamoxifen therapy, and a short progression-free and overall survival after start of treatment for recurrent disease. In Cox multivariate analyses for response to therapy and for (progression-free) survival, corrected for age/menopausal status, disease-free interval, site of relapse and steroid hormone receptor status, PSA was an independent variable of poor prognosis. It is concluded that the level of PSA in cytosols of primary breast tumours might be a marker to select breast cancer patients who may benefit from systemic tamoxifen therapy. © 1999 Cancer Research Campaign

Keywords: prostate-specific antigen, breast cancer prognosis, response to therapy

Full Text

The Full Text of this article is available as a PDF (96.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen P. A., Kjøller L., Christensen L., Duffy M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997 Jul 3;72(1):1–22. doi: 10.1002/(sici)1097-0215(19970703)72:1<1::aid-ijc1>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  2. Campbell P. G., Novak J. F., Yanosick T. B., McMaster J. H. Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology. 1992 Mar;130(3):1401–1412. doi: 10.1210/endo.130.3.1371448. [DOI] [PubMed] [Google Scholar]
  3. Catalona W. J., Smith D. S., Ratliff T. L., Dodds K. M., Coplen D. E., Yuan J. J., Petros J. A., Andriole G. L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991 Apr 25;324(17):1156–1161. doi: 10.1056/NEJM199104253241702. [DOI] [PubMed] [Google Scholar]
  4. Cohen P., Graves H. C., Peehl D. M., Kamarei M., Giudice L. C., Rosenfeld R. G. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab. 1992 Oct;75(4):1046–1053. doi: 10.1210/jcem.75.4.1383255. [DOI] [PubMed] [Google Scholar]
  5. Cohen P., Peehl D. M., Graves H. C., Rosenfeld R. G. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol. 1994 Sep;142(3):407–415. doi: 10.1677/joe.0.1420407. [DOI] [PubMed] [Google Scholar]
  6. Cullen K. J., Yee D., Sly W. S., Perdue J., Hampton B., Lippman M. E., Rosen N. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res. 1990 Jan 1;50(1):48–53. [PubMed] [Google Scholar]
  7. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  8. Diamandis E. P. Prostate specific antigen--new applications in breast and other cancers. Anticancer Res. 1996 Nov-Dec;16(6C):3983–3984. [PubMed] [Google Scholar]
  9. Duffy M. J., O'Grady P., Devaney D., O'Siorain L., Fennelly J. J., Lijnen H. J. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer. 1988 Aug 1;62(3):531–533. doi: 10.1002/1097-0142(19880801)62:3<531::aid-cncr2820620315>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  10. Duffy M. J. Proteases as prognostic markers in cancer. Clin Cancer Res. 1996 Apr;2(4):613–618. [PubMed] [Google Scholar]
  11. Ferguson R. A., Yu H., Kalyvas M., Zammit S., Diamandis E. P. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem. 1996 May;42(5):675–684. [PubMed] [Google Scholar]
  12. Figueroa J. A., Yee D. The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer. Breast Cancer Res Treat. 1992;22(1):81–90. doi: 10.1007/BF01833336. [DOI] [PubMed] [Google Scholar]
  13. Foekens J. A., Look M. P., Peters H. A., van Putten W. L., Portengen H., Klijn J. G. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751–756. doi: 10.1093/jnci/87.10.751. [DOI] [PubMed] [Google Scholar]
  14. Foekens J. A., Portengen H., Look M. P., van Putten W. L., Thirion B., Bontenbal M., Klijn J. G. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer. 1994 Dec;70(6):1217–1223. doi: 10.1038/bjc.1994.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Foekens J. A., Portengen H., van Putten W. L., Peters H. A., Krijnen H. L., Alexieva-Figusch J., Klijn J. G. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res. 1989 Nov 1;49(21):5823–5828. [PubMed] [Google Scholar]
  16. Foekens J. A., Schmitt M., van Putten W. L., Peters H. A., Bontenbal M., Jänicke F., Klijn J. G. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 1992 Nov 1;52(21):6101–6105. [PubMed] [Google Scholar]
  17. Giai M., Yu H., Roagna R., Ponzone R., Katsaros D., Levesque M. A., Diamandis E. P. Prostate-specific antigen in serum of women with breast cancer. Br J Cancer. 1995 Sep;72(3):728–731. doi: 10.1038/bjc.1995.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kanety H., Madjar Y., Dagan Y., Levi J., Papa M. Z., Pariente C., Goldwasser B., Karasik A. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab. 1993 Jul;77(1):229–233. doi: 10.1210/jcem.77.1.7686915. [DOI] [PubMed] [Google Scholar]
  19. Lahti E. I., Knip M., Laatikainen T. J. Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer. 1994 Jul 15;74(2):618–624. doi: 10.1002/1097-0142(19940715)74:2<618::aid-cncr2820740213>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  20. Lai L. C., Erbas H., Lennard T. W., Peaston R. T. Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer. Int J Cancer. 1996 Jun 11;66(6):743–746. doi: 10.1002/(SICI)1097-0215(19960611)66:6<743::AID-IJC6>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  21. Lalou C., Silve C., Rosato R., Segovia B., Binoux M. Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. Endocrinology. 1994 Dec;135(6):2318–2326. doi: 10.1210/endo.135.6.7527330. [DOI] [PubMed] [Google Scholar]
  22. Lehrer S., Terk M., Piccoli S. P., Song H. K., Lavagnini P., Luderer A. A. Reverse transcriptase-polymerase chain reaction for prostate-specific antigen may be a prognostic indicator in breast cancer. Br J Cancer. 1996 Sep;74(6):871–873. doi: 10.1038/bjc.1996.450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Levesque M. A., Clark G. M., Yu H., Diamandis E. P. Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. Br J Cancer. 1995 Sep;72(3):720–727. doi: 10.1038/bjc.1995.400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Levesque M., Hu H., D'Costa M., Diamandis E. P. Prostate-specific antigen expression by various tumors. J Clin Lab Anal. 1995;9(2):123–128. doi: 10.1002/jcla.1860090209. [DOI] [PubMed] [Google Scholar]
  25. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest. 1985 Nov;76(5):1899–1903. doi: 10.1172/JCI112185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lønning P. E., Hall K., Aakvaag A., Lien E. A. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res. 1992 Sep 1;52(17):4719–4723. [PubMed] [Google Scholar]
  27. Manni A., Badger B., Wei L., Zaenglein A., Grove R., Khin S., Heitjan D., Shimasaki S., Ling N. Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells in vivo: evidence for stromal epithelial interactions. Cancer Res. 1994 Jun 1;54(11):2934–2942. [PubMed] [Google Scholar]
  28. Melegos D. N., Yu H., Ashok M., Wang C., Stanczyk F., Diamandis E. P. Prostate-specific antigen in female serum, a potential new marker of androgen excess. J Clin Endocrinol Metab. 1997 Mar;82(3):777–780. doi: 10.1210/jcem.82.3.3792. [DOI] [PubMed] [Google Scholar]
  29. Mignatti P., Rifkin D. B. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 1993 Jan;73(1):161–195. doi: 10.1152/physrev.1993.73.1.161. [DOI] [PubMed] [Google Scholar]
  30. Nicholson S., Sainsbury J. R., Halcrow P., Chambers P., Farndon J. R., Harris A. L. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet. 1989 Jan 28;1(8631):182–185. doi: 10.1016/s0140-6736(89)91202-6. [DOI] [PubMed] [Google Scholar]
  31. Oesterling J. E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991 May;145(5):907–923. doi: 10.1016/s0022-5347(17)38491-4. [DOI] [PubMed] [Google Scholar]
  32. Osborne C. K., Coronado E. B., Kitten L. J., Arteaga C. I., Fuqua S. A., Ramasharma K., Marshall M., Li C. H. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol. 1989 Nov;3(11):1701–1709. doi: 10.1210/mend-3-11-1701. [DOI] [PubMed] [Google Scholar]
  33. Pollak M., Costantino J., Polychronakos C., Blauer S. A., Guyda H., Redmond C., Fisher B., Margolese R. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst. 1990 Nov 7;82(21):1693–1697. doi: 10.1093/jnci/82.21.1693. [DOI] [PubMed] [Google Scholar]
  34. Ravdin P. M., Green S., Dorr T. M., McGuire W. L., Fabian C., Pugh R. P., Carter R. D., Rivkin S. E., Borst J. R., Belt R. J. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992 Aug;10(8):1284–1291. doi: 10.1200/JCO.1992.10.8.1284. [DOI] [PubMed] [Google Scholar]
  35. Schmitt M., Harbeck N., Thomssen C., Wilhelm O., Magdolen V., Reuning U., Ulm K., Höfler H., Jänicke F., Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost. 1997 Jul;78(1):285–296. [PubMed] [Google Scholar]
  36. Stamey T. A., Yang N., Hay A. R., McNeal J. E., Freiha F. S., Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987 Oct 8;317(15):909–916. doi: 10.1056/NEJM198710083171501. [DOI] [PubMed] [Google Scholar]
  37. Yee D., Sharma J., Hilsenbeck S. G. Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. J Natl Cancer Inst. 1994 Dec 7;86(23):1785–1789. doi: 10.1093/jnci/86.23.1785. [DOI] [PubMed] [Google Scholar]
  38. Yu H., Diamandis E. P., Levesque M., Asa S. L., Monne M., Croce C. M. Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Res. 1995 Apr 15;55(8):1603–1606. [PubMed] [Google Scholar]
  39. Yu H., Diamandis E. P., Levesque M., Giai M., Roagna R., Ponzone R., Sismondi P., Monne M., Croce C. M. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat. 1996;40(2):171–178. doi: 10.1007/BF01806212. [DOI] [PubMed] [Google Scholar]
  40. Yu H., Diamandis E. P., Sutherland D. J. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem. 1994 Apr;27(2):75–79. doi: 10.1016/0009-9120(94)90015-9. [DOI] [PubMed] [Google Scholar]
  41. Yu H., Diamandis E. P., Zarghami N., Grass L. Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat. 1994;32(3):291–300. doi: 10.1007/BF00666006. [DOI] [PubMed] [Google Scholar]
  42. Yu H., Giai M., Diamandis E. P., Katsaros D., Sutherland D. J., Levesque M. A., Roagna R., Ponzone R., Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. 1995 May 15;55(10):2104–2110. [PubMed] [Google Scholar]
  43. Yu H., Levesque M. A., Clark G. M., Diamandis E. P. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res. 1998 Jun;4(6):1489–1497. [PubMed] [Google Scholar]
  44. Yu H., Levesque M. A., Khosravi M. J., Papanastasiou-Diamandi A., Clark G. M., Diamandis E. P. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. Br J Cancer. 1996 Oct;74(8):1242–1247. doi: 10.1038/bjc.1996.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Zarghami N., Grass L., Diamandis E. P. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer. 1997;75(4):579–588. doi: 10.1038/bjc.1997.101. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES